Physician profile
Janine A Gundel
NPI 1790070464
$1,648.46
in general payments reported to CMS, 2019-2025
12 companies · $1,501 in 2025
The $1,501 reported for 2025 was more than what 94% of Clinical Nurse Specialist providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $131 · 2023: $16.43 · 2025: $1,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $796 · Food and Beverage: $714 · Travel and Lodging: $7.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $796.25 |
| Food and Beverage | $714.05 |
| Travel and Lodging | $7.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $931.03 | 2025 | Epkinly |
| Janssen Biotech, INC. | $184.35 | 2025 | Rybrevant, Carvykti |
| Amgen INC. | $130.95 | 2025 | Imdelltra (Amg757) |
| Alkermes, INC. | $96.85 | 2022 | |
| Janssen Scientific Affairs, LLC | $80.21 | 2025 | Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals Lp | $52.38 | 2025 | Datroway |
| Indivior INC. | $34.88 | 2023-2025 | Sublocade |
| Neurocrine Biosciences, INC. | $34.31 | 2022 | |
| Merck Sharp & Dohme LLC | $30.18 | 2025 | Reblozyl, Keytruda, Welireg |
| Immunocore Limited | $27.30 | 2025 | Kimmtrak |
| Incyte Corporation | $23.48 | 2025 | Jakafi |
| Daiichi Sankyo INC. | $22.54 | 2025 | Enhertu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janine Gundel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.